Aardvark Therapeutics Share Price Today: Live Updates & Key Insights

Aardvark Therapeutics share price today is $4.1, up -16.94%. The stock opened at $4.91 against the previous close of $4.9, with an intraday high of $4.915 and low of $4.055.

Aardvark Therapeutics Share Price Chart

Aardvark Therapeutics

us-stock
To Invest in {{usstockname}}
us-stock

Aardvark Therapeutics Share Price Performance

$4.1 -0.1694(-16.94%) AARD at 23 Mar 2026 11:51 AM Biotechnology
Lowest Today 4.055
Highest Today 4.915
Today’s Open 4.91
Prev. Close 4.9
52 Week High 17.94
52 Week Low 4.06
Day’s Range: Low 4.055 High 4.915
52-Week Range: Low 4.06 High 17.94
1 day return -
1 Week return -24.16
1 month return -67.43
3 month return -71.97
6 month return -64.17
1 year return -56.17
3 year return -
5 year return -
10 year return -

Aardvark Therapeutics Institutional Holdings

Aardvark Therapeutics Market Status

Strong Buy: 2

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

Aardvark Therapeutics Fundamentals

Market Cap 88.62 M

PB Ratio 0.7259

PE Ratio 0.0

Enterprise Value -36.97 M

Total Assets 77.51 M

Volume 437653

Aardvark Therapeutics Company Financials

About Aardvark Therapeutics & investment objective

Company Information Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in the Phase 2 clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from the treatment of craniopharyngioma, including surgery or radiation. The company is also developing ARD-201, which is in the Phase 1 clinical trial for the treatment of obesity. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Organisation Biotechnology

Employees 33

Industry Biotechnology

CEO Dr. Tien-Li Lee M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Aardvark Therapeutics FAQs

What is the share price of Aardvark Therapeutics today?

The current share price of Aardvark Therapeutics is $4.1.

Can I buy Aardvark Therapeutics shares in India?

Yes, Indian investors can buy Aardvark Therapeutics shares by opening an international trading and demat account with Motilal Oswal.

How to buy Aardvark Therapeutics shares in India?

You can easily invest in Aardvark Therapeutics shares from India by:

Can I buy fractional shares of Aardvark Therapeutics?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Aardvark Therapeutics?

Aardvark Therapeutics has a market cap of $88.62 M.

In which sector does Aardvark Therapeutics belong?

Aardvark Therapeutics operates in the Biotechnology sector.

What documents are required to invest in Aardvark Therapeutics stocks?

To invest, you typically need:

What is the PE and PB ratio of Aardvark Therapeutics?

The PE ratio of Aardvark Therapeutics is N/A and the PB ratio is 0.73.